NCT07691255 MELanoma Brain Metastasis Treated With CYberknife
| NCT ID | NCT07691255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Melanoma (Skin Cancer) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-08-25 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-08-25 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life. In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma. This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes. Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 * Written informed consent for treatment and research purposes * Melanoma Brain Metastases (MBM) diagnosed with brain MRI/CT * MBM treatable with stereotactic radiotherapy * Systemic therapy (immunotherapy, target therapy, or both) is allowed, as concurrent or non-concurrent treatment with stereotactic radiotherapy Exclusion Criteria: * Leptomeningeal neoplastic infiltration * Previous whole-brain radiotherapy or surgical removal of brain metastases * Patients with histological diagnosis of non-cutaneous melanoma (e.g. uveal melanoma)
Contact & Investigator
Samantha Dicuonzo, MD
PRINCIPAL INVESTIGATOR
European Institute of Oncology
Frequently Asked Questions
Who can join the NCT07691255 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Melanoma (Skin Cancer). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07691255 currently recruiting?
Yes, NCT07691255 is actively recruiting participants. Contact the research team at samantha.dicuonzo@ieo.it for enrollment information.
Where is the NCT07691255 trial being conducted?
This trial is being conducted at Milan, Italy, Milan, Italy.
Who is sponsoring the NCT07691255 clinical trial?
NCT07691255 is sponsored by European Institute of Oncology. The principal investigator is Samantha Dicuonzo, MD at European Institute of Oncology. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.